

Integrative analyses identify potential key genes and pathways in Keshan disease using whole-exome sequencing

Jichang Huang^{1#}, Chenqing Zheng^{2#}, Rong Luo^{1#}, Mingjiang Liu³, Qingquan Gu⁴, Jinshu Li⁵, Xiushan Wu⁶, Zhenglin Yang³, Xia Shen^{2*}, Xiaoping Li^{3*}

1 Institute of Geriatric Cardiovascular Disease, Chengdu Medical College, Chengdu, People's Republic of China

2 State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, China

3 Department of Cardiology, Hospital of the University of Electronic Science and Technology of China and Sichuan Provincial People's Hospital, Chengdu, Sichuan, China

4 Shenzhen RealOmics (Biotech) Co., Ltd., Shenzhen, China

5 Institute of Endemic Disease, Center for Disease Control and Prevention of Sichuan Province, Chengdu, Sichuan, China

6 The Center of Heart Development, College of Life Sciences, Hunan Normal University, Changsha, China

#, These authors contributed equally to this work.

*, Authors for correspondence.

Abstract

Keshan disease (KD), an endemic heart disease with multifocal necrosis and replacement fibrosis of the myocardium, is still a nightmare situation for human health. However, molecular mechanism in the pathogenesis of KD remains unclear. Herein, blood samples were collected from 68 KD patients and 100 controls, and we systematically analyzed mutation profiles using whole-exome sequencing (WES). Causative genes of dilated cardiomyopathy (DCM), gene-based burden analysis, disease and pathway enrichment analysis, and protein-protein interaction (PPI) network analysis were performed. Of the 98 DCM-causative genes, 106 rare variants in 28 genes were detected in KD patients with minor allele frequency (MAF) < 0.001. Gene-based burden analysis, PPI network analysis, and automated Phenolyzer analysis were performed to prioritize 199 candidate genes, which combined with 98 DCM-causative genes, and reference genes from gene microarray or proteomics in KD. Then, 19 candidate pathogenic genes were selected, and 9 candidate genes were identified using PPI analysis, including *HIF1A*, *GART*, *ALAD*, *VCL*, *DTNA*, *NEXN*, *INPPL1*, *NOS3*, and *JAK2*. The 199 candidate genes were further analyzed using disease enrichment with CTD database and PPI analysis, and 21 candidate genes were identified. By combining with disease enrichment and PPI analysis, 7 Selenium (Se)-related genes were further identified, including *ALAD*, *RBM10*, *GSN*, *GGT1*, *ADD1*, *PARP1*, and *NOS3*. Based on the gene function and data validation, *NEXN*, *TAF1C*, *FUT4*, *ALAD*, *ZNF608*, and *STX2* were the most likely pathogenic genes in KD. Notably, *ALAD* is the only candidate pathogenic gene identified by four different analyses, and its homozygous mutant mice could affect heart development and cause death.

Keywords: Keshan disease, dilated cardiomyopathy, whole-exome sequencing, gene-based burden analysis, automated Phenolyzer analysis

1. Introduction

Keshan disease (KD), a dilated cardiomyopathy, still has a high mortality. KD was firstly noted in 1935 in Keshan County, Northeast China [1], whilst it was reported in Nagano Prefecture in Japan and northern mountains in North Korea in the 1950s as well [2]. It mainly invades the myocardium, manifested as myocardial degeneration, chronic heart failure, various arrhythmias and even sudden death [3]. The effective treatments used in Keshan disease are not available till now.

Selenium deficiency is believed as the direct cause for KD occurrence [4]. Selenium supplementation for the treatment of Keshan disease has been shown significant clinical benefits, while it is difficult to explain the seasonal or annual variation of KD occurrence [5, 6]. Moreover, KD disease also occurs in some regions where selenium is not lacking [7]. Indeed, there is increasing evidence that Keshan disease is related to polymorphisms, familial clustering, and mutations of related genes, indicating that genetic factors are important promoters for the etiology and molecular mechanism of this disease [8]. To explore the possible mechanism, genetic analysis should be performed.

Recently, owing to the advancement in whole exome sequencing (WES), it has been successfully used to discover disease-related genes of for multiple Mendelian or non-Mendelian diseases [9]. However, Genome-Wide Association Studies (GWAS) focuses on common mutations ($MAF \geq 5\%$), and its impact is small, $RR \approx 1.2-1.5$ [10]. In addition, the large number of GWAS SNPs explains a small part of the heritability of the disease [10]. Compared to common variant studies, individual SNP analysis in rare variant studies is seriously underpowered [11]. Recent advances in gene-based burden analysis might help to tackle some of these limitations. The approach was based on gene-based burden analysis, in which the total frequency of “qualifying variants” of each gene is compared between cases and controls [11]. Therefore, we hypothesize that the application of this more integrated approach may help elucidate the genetic etiology of Keshan disease.

As far as we know, the pathogenic gene of Keshan disease has not been reported. In

this study, we approached WES to identify potential key genes by gene-based burden analysis, KEGG pathway enrichment, and protein-protein interaction (PPI) analyses for KD disease.

2. Results

2.1 Clinical baseline data of KD patients

The subjects, including 68 KD patients and 100 healthy individuals, were recruited into this study. Of 68 KD patients, it is defined as left ventricle enlargement (men > 55mm, women > 50mm) and reduced ejection fraction (LVEF < 50%) obtained by echocardiography. Among the KD patients, 30 females (44.1%, 30/68) and 38 males (56.7%, 38/68), a mean age 56.81 ± 11.01 years old, were included in our study. As shown in Table 1, the percentage of patients with NYHA class II/III, left bundle-branch block (LBBB), right bundle-branch block (RBBB), intraventricular conduction delay, ventricular premature beats, atrial fibrillation were 83.8% (57/68), 7.4% (5/68), 14.7% (10/68), 26.5% (18/68), 22.1% (15/68), 13.2% (9/68), respectively. The left ventricular diameter was 55.33 ± 10.97 mm.

Table 1. Demographic baseline of patients

Variables	Total patients (n = 68)
Sex, male (%)	38 (56.7)
Age, year	56.81 ± 11.01
BMI, kg/m ²	57.24 ± 10.83
Smoking (%)	16 (23.5)
Drinking (%)	16 (23.5)
NYHA II/III (%)	57 (83.8)
History of cardiovascular disease (%)	28 (41.2)
The left atrium diameter (mm)	38.24 ± 8.52
The left ventricular diameter (mm)	55.33 ± 10.97
The right ventricular diameter (mm)	22.00 ± 3.20
LBBB (%)	5 (7.4)
RBBB (%)	10 (14.7)
Intraventricular conduction delay (%)	18 (26.5)
Ventricular premature beats (%)	15 (22.1)
Atrial fibrillation (%)	9 (13.2)

2.2 Rare variants of DCM-causative genes in KD patients

To elucidate the possible genetic mechanisms of KD pathogenesis, a dilated cardiomyopathy, rare variants of DCM-causative genes were measured in accordance with minor allele frequency (MAF) below 0.1% in the ExAC and the database for the

1000 Genomes Project [12,13]. There are various rare variants of DCM-causative genes in KD patients as follows: 34 rare variants in *TTN* (n = 34), 20 in *OBSCN* (n = 20), 4 in *LAMA4* (n = 4), 2 in *MYBPC3* (n = 2), 2 in *VCL* (n = 2), 3 in *FHL2* (n = 3), 3 in *ZBTB17* (n = 3), 2 in *RBM20* (n = 2), 2 in *ANKRD1* (n = 2), 2 in *KCNQ1* (n = 2), 4 in *DMD* (n = 4), 2 in *MYPN* (n = 2), x in *MYH7* (n = 2), 2 in *BRAF* (n = 2), 4 in *FLNC* (n = 4), 1 in *MYH6* (n = 1), 3 in *SYNM* (n = 3), 2 in *RYR2* (n = 2), 1 in *ABCC9* (n = 1), 1 in *DSC2* (n = 1), 1 in *FKRP* (n = 1), 1 in *FKTN* (n = 1), 2 in *LDB3* (n = 2), 2 in *SCN5A* (n = 2), 1 in *TXNRD2* (n = 1), 1 in *SOS1* (n = 1), 1 in *MURC* (n = 1), 1 in *DSG2* (n = 1) as shown in Supplementary Table S2 and Figure 1. These genes were associated with various biological processes, including sarcomere, cytoskeleton, desmosomes, sarcoplasmic reticulum, nucleus, ion channel, extracellular matrix, and mitochondria.




Figure 1. The number of rare variants and cases in DCM-causative genes with MAF < 0.001(A) and MAF < 0.01 (B). The blue column shows the number of rare variants of DCM-causative genes, and the yellow column show the number of patients with rare variants.

As the incidence of KD was dramatically reduced and a relatively small sample sizes were selected in this study, so we also have applied rare variants with MAF below 1% to further analyze. In total, the 253 rare variants were identified in 52 genes as shown in Figure 1. These genes were related to sarcomere, cytoskeleton, desmosomes, sarcoplasmic reticulum, nucleus, ion channel, extracellular matrix, and mitochondria. These results were similar to rare variants with MAF below 0.1%, further suggesting that these biological processes may play an important role in KD pathogenesis.

2.3 Gene-based burden analysis and identification of candidate genes

To further reveal the aggregate association of rare variants, gene-based burden analysis were introduced to obtain a gene-level mutational profile (MAF < 0.001, MAF < 0.01 or MAF < 0.05; p -value < 0.05). Manhattan figures and Q-Q plots of gene-based GWAS results were displayed in Supplemental Figure 1. Rare variants of 199 genes were listed in Table S3. Among these genes, five DCM-causative genes, including *MYBPC3*, *OBSCN*, *DTNA*, *NEXN*, and *VCL* were identified in KD patients.

To select the potential pathogenic genes from 199 genes, comprehensive protein-protein interactions (PPI) were proposed to prioritize candidate genes, which combined with 98 DCM-causative genes, reference genes from gene microarray in KD, and reference genes from proteomics in KD [14]. Top 30 genes were selected to constitute gene sets from DCM-causative genes, gene microarray, and proteomics, respectively. Then, a Venn diagram was performed for intersect genes selection from three-gene sets. There were 3 genes in all three-gene sets in Figure 2A, including *HIF1A*, *GART*, and *ALAD*. 16 intersect genes were screened in any two-gene sets: *MYOM1*, *VCL*, *DTNA*, *KIAA1217*, *RBMX*, *NEXN*, *MYOT*, *ABCB5*, *LUZP1*, *JAK2*, *ERAL1*, *INPPL1*, *ETV4*, *NOS3*, *RICTOR*, and *LDHAL6B*. Notably, *VCL*, *DTNA*, and *NEXN* were identified in DCM as causative genes.

The disease enrichment analysis was conducted to identify the relationship between diseases and these 19 genes through the Comparative Toxicogenomics Database (CTD) database. The top 20 enriched diseases are shown in Figure 2B. Of the

top 20 diseases, 10 diseases might be closely related with KD, including 1 fibrosis, and 9 cardiovascular diseases.




Figure 2. Identification and functional annotation of candidate genes. (A) The overlap of genes from burden analysis in DCM-causative genes, gene microarray, and proteomics. (B) The bubble chart of top

20 diseases with 18 overlapping genes enriched by the Comparative Toxicogenomics Database (CTD) database. (C) The bubble chart of top 20 pathways with eighteen overlapping genes enriched by Reactome database. (D) The Gene Ontology (GO) analysis of eighteen overlapping genes. (E) The protein–protein interactions (PPI) analysis of eighteen overlapping genes.

The *Kyoto Encyclopedia of Genes and Genomes* (KEGG) pathway enrichment analysis revealed that 18 candidate genes might be associated with signaling by VEGF, immune system, signaling by interleukins, paradoxical activation of RAF signaling, and MAPK family signaling cascades (Figure 2C). In addition, the Gene Ontology (GO) analysis revealed that these genes might be related to contractile fiber, myofibril, sarcolemma, Z disc, I band, vesicle, sarcomere, and actin binding (Figure 2D). The protein–protein interactions (PPI) analysis was performed to further screen the most likely candidate genes, and there were 9 genes constituting PPI network, including *HIF1A*, *GART*, *ALAD*, *VCL*, *DTNA*, *NEXN*, *INPPL1*, *NOS3*, and *JAK2* (Figure 2E).

Based on the above-related analysis and the previous functional study, the candidate genes (*HIF1A*, *GART*, *ALAD*, *VCL*, *DTNA*, *NEXN*, *INPPL1*, *NOS3*, and *JAK2*) were further considered as the most likely genes.

2.4 Enriched disease analysis and functional annotation of candidate genes

The disease enrichment analysis was conducted to identify the relationship between diseases and these genes through the CTD database. A total of 59 different diseases were significantly enriched by the genes with an $MAF < 0.001$, $MAF < 0.01$, and $MAF < 0.05$, respectively. The top 30 enriched diseases are shown in Figure 4. Of the top 30 diseases, 5 cardiovascular diseases might be closely related with KD. Subsequently, except for the top 30 enriched diseases, there were 7 cardiovascular diseases.

Based on the analysis given above, we identified 35 candidate pathogenic genes: *ADD1*, *ADORA3*, *ALAD*, *ASAHI*, *BRAP*, *CANX*, *COL5A1*, *CRHR2*, *DTNA*, *FUT4*, *GGT1*, *GP1BA*, *GSN*, *HECTD4*, *HIF1A*, *INPPL1*, *IRF2BPL*, *JAK2*, *MYBPC3*, *MYOT*, *NEXN*, *NOS3*, *PARP1*, *PLD1*, *PRKAG2*, *PSEN2*, *RBM10*, *SCN10A*, *SCN1B*, *SCNNIG*,

SLC27A6, *SUN1*, *TFAP2B*, *TFRC*, and *VCL* (Figure 3A). The mutation profile of 35 genes was shown in heat map with an $MAF < 0.001$, $MAF < 0.01$, and $MAF < 0.05$ (Figure 3B). Notably, 4 DCM-causative genes, including *MYBPC3*, *DTNA*, *NEXN*, and *VCL* were discovered in KD patients. These 35 genes were associated with various biological processes, including immune system, RAF signaling pathway, axon guidance, signaling by interleukins, HIF-1 signaling pathway, MAPK signaling, and IRS-mediated signaling (Figure 3C).

To further elucidate the pathogenic genes from 35 candidate genes, PPI analysis were proposed to prioritize candidate disease genes, which combined with genes from microarray in KD, and genes from proteomics in KD. There were 21 genes constituting 4 networks, including network 1 (*SCN10A*, *SCN1B*, and *SCNN1G*), network 2 (*MYOT*, *GSN*, *NEXN*, *VCL*, *DTNA*, *MYBPC3*, and *PRKAG2*), network 3 (*GGT1*, *CANX*, *TFRC*, *FUT4*, *JAK2*, *INPPL1*, *NOS3*, *HIF1A*, and *PARP1*), network 4 (*PSEN2*, and *PLD1*) in Figure 3D.

The PPI analysis was further proposed to prioritize candidate disease genes, which combined with genes from proteomics in KD. There were 27 genes, including *ADD1*, *ADORA3*, *ALAD*, *CANX*, *COL5A1*, *CRHR2*, *DTNA*, *FUT4*, *GGT1*, *GP1BA*, *GSN*, *HIF1A*, *INPPL1*, *JAK2*, *MYBPC3*, *MYOT*, *NEXN*, *NOS3*, *PARP1*, *PLD1*, *PRKAG2*, *PSEN2*, *SCN10A*, *SCN1B*, *SCNN1G*, *TFRC*, and *VCL* in Figure 3E.




Figure 3. Enriched disease analysis and functional annotation of candidate genes. (A) The bubble chart of top 20 diseases with 199 genes from burden analysis enriched by the CTD database. (B) The mutation profile of 35 candidate genes. (C) The bubble chart of top 20 pathways with eighteen overlapping genes enriched by Reactome database. (D) The PPI analysis of 35 candidate genes, genes from gene microarray. Purple, and yellow circles represent genes from our study and gene microarray in previous study, respectively. (E) The PPI analysis of 35 candidate genes and genes from proteomics. Purple and blue

circles represent genes from our study and proteomics in previous study, respectively.

2.5 Screening of the Se-related genes in gene-based burden results

Because Se deficiency was closely connected with KD, we further identified 24 candidate Se-related genes from gene-based burden results through the CTD database: *ADD1*, *AK2*, *ALAD*, *ATRX*, *DDOST*, *FLRT3*, *GGT1*, *GSN*, *HIPK2*, *HMBS*, *KDM6B*, *KIAA0100*, *MINK1*, *MTCH2*, *NOLC1*, *NOS3*, *PARP1*, *PIGK*, *PKM*, *RBM10*, *SDC3*, *TNPO1*, *UQCRC1*, *YLPM1* (Figure 4A). The KEGG pathway enrichment analysis revealed that 18 candidate genes might be associated with metabolism, heme biosynthesis, caspase-mediated cleavage of cytoskeletal proteins, and neutrophil degranulation (Figure 4B).

To further explore candidate Se-related pathogenic genes in KD patients, the disease enrichment analysis was performed to identify the relationship between diseases and Se-related genes through the CTD database. The top 20 enriched diseases are shown in Figure 4. Among the top 20 diseases, 2 cardiovascular diseases might be closely related with KD. Then, 7 gene genes were identified, including *ALAD*, *RBM10*, *GSN*, *GGT1*, *ADD1*, *PARP1*, and *NOS3*.




Figure 4. Identification and functional annotation of Se-related genes. (A) The overlap of genes from burden analysis and Se-related genes from CTD database. (B) The bubble chart of top 20 pathways with 24 overlapping genes enriched by Reactome database. (C) The bubble chart of top 20 diseases with 24 genes enriched by CTD database. (D) The PPI analysis of 24 Se-related genes and genes from gene microarray. Purple and yellow circles represent genes from our study and gene microarray in previous study, respectively. (E) The PPI analysis of 24 Se-related genes and genes from proteomics. Purple and blue circles represent genes from our study and proteomics in previous study, respectively.

To further elucidate the pathogenic genes from 24 candidate Se-related genes, PPI analysis were proposed to prioritize candidate disease genes, which combined with genes from microarray in KD, and genes from proteomics in KD. As shown in Figure 4, top 9 significant genes in accordance with scores and nodes were *NOS3*, *PARP1*, *ATRX*, *GSN*, *HMBS*, *PKM*, *ALAD*, *GGT1*, and *KDM6B*.

Taking into account the functional role of genes and previous research, *GSN*, *ADD1*, and *NOS3* are the most likely Se-related genes contributing to the pathogenesis of KD.

2.6 Proofreading and validation for the candidate genes

To verify the reliability of these selected genes, we carried out proofreading and validation with UK Biobank, which providing exome-sequence data and 791 phenotypes data from 49,960 participants. Because Keshan disease has a strong correlation with chronic heart failure, all related phenotypes (7) were selected from all the phenotypes (791). For 199 genes from burden analysis, 7 related phenotypes (Data set 1) were further respectively compared with 17 different disease categories (Data set 2) and all the phenotypes (Data set 3) with Fisher's exact test methods, and the top 20 significant genes were illustrated in Figure 5, including *NEXN*, *TAF1C*, *FUT4*, *ALAD*, *ZNF608*, *STX2*, *SCNN1G*, *MINK1*, *YLPM1*, *ITGA10*, *MYBPC3*, *TYW1*, *GSTZ1*, *NPHP4*, *PHLPP1*, *FANCD2*, *NMNAT1*, *COL5A1*, *AHNAK*, and *DMRTA2*. Remarkably, *NEXN*, *TAF1C*, *FUT4*, *ALAD*, *ZNF608*, and *STX2* were clustered together and relatively different in 17 different disease categories and all categories. Notably, one DCM-causative gene, *NEXN* was found among these 6 genes.

Clinical indicators were further combined to analyze patients with and without the six genes mutations. The left ventricular diameter were significant different between carried mutation and non-carried mutation patients (Figure 5B). The QT and QTc were significant different between carried mutation and non-carried mutation female patients with the six genes, while not in male patients (Figure 5C and 5D).




Figure 5. Validation for the candidate genes. (A) The candidate genes from burden analysis were validated with UK Biobank. (B) The left ventricular diameter was analyzed between carried and non-carried mutation patients with the six genes. (C) The left ventricular diameter was analyzed between carried and non-carried mutation patients with the six genes. (D) The QTc was analyzed between carried and non-carried mutation patients with the six genes.

2.7 Proofreading and validation for *ALAD*

To find the most likely pathogenic genes in KD, the candidate genes from four different analyses were taken intersection. Notably, *ALAD* is the only candidate pathogenic gene identified by all analyses, indicating that the gene is highly repetitive and reliable.

We further confirmed the phenotype based on the information of *ALAD* deletion mutants in the mouse gene database MGI (Table 1), and found that the *ALAD* homozygous mutants were lethal before the formation of the atrial septum, indicating that *ALAD* is important in the development of the heart. *ALAD* heterozygous mutants have gender differences in phenotypes, such as reduced grip strength in heterozygous

male mice and decreased average red blood cell volume in female mice. This suggesting that *ALAD* might play an important role in the pathogenesis of KD.

Table 1 Phenotypic information of *ALAD* deletion mutants in MGI database

	<i>Alad</i> ^{em1(IMPC)Tep} / <i>Alad</i> ^{em1(IMPC)Tep}		<i>Alad</i> ^{em1(IMPC)Tep} / <i>Alad</i> ⁺	
			♀	♂
Behavior/neurological				
Decreased grip strength				√
Hematopoietic system				
Decreased mean corpuscular volume			√	
Homeostasis/metabolism				
Increased circulating triglyceride level			√	√
Mortality/aging				
Embryonic lethality prior to organogenesis		√		
Prenatal lethality prior to heart atrial septation		√		
Prewaning lethality, complete penetrance		√		

3 Discussion

Keshan disease is described primarily as dilated cardiomyopathy, manifested as systolic and diastolic dysfunction, heart failure, various arrhythmias and even sudden death [3]. The effective treatments used in KD are not available so far. Fortunately, an in-depth understanding of the molecular mechanisms underlying DCM opens the door to explore Keshan disease [12,13]. As for KD, we identified various DCM-causative genes, encoding for diverse proteins of the sarcomere (*MYH6*, *MYH7*, *MYBPC3*, and *MYPN*), cytoskeleton (*TTN*, *ACTN2*, *LDB3*, *SYNM*, *DMD*, *FHL2*, *FKTN*, *VCL*, *FLNC*, *MURC*, and *NEBL*), desmosomes (*DSP*, *DSC2*, *DSG2*, *PKP2*, and *CTNNA3*), nucleus (*RBM20*, *ANKRD1*, *PRDM16*, *ZBTB17*, *ALPK3*, and *LRRC10*), ion channel (*SCN5A*, *ABCC9*, and *KCNQ1*), extracellular matrix (*LAMA2*, and *LAMA4*), and mitochondria (*TXNRD2*). There are various these known biological processes, including the sarcomere, cytoskeleton, and ion channel, leading to systolic and diastolic dysfunction in DCM as previous reported. These results suggested that these genes might be involved in the regulation of KD pathogenesis.

Keshan disease tends to be accompanied with conductive arrhythmia, congested heart failure, and cardiogenic shock, in which ion channels may be the important mediators. These three sodium channel genes, *SCN10A*, *SCN1B*, and *SCNN1G*, were related to each other through PPI analysis. The mutation of *SCN10A*, a sodium channel, was linked to prolonged cardiac conduction in human, and *SCN10A*-deficient mice exhibited a shorter PR interval than controls [15]. Furthermore, *SCN10A* mutation was even found to induce sudden cardiac death [16]. In addition, the mutation of *SCN1B* (encoding the sodium channel β 1 subunit), impacted action potential generation in cardiomyocytes [17]. Multiple mutations of *SCN1B* were detected in patients with arrhythmogenic right ventricular cardiomyopathy [18]. *SCNN1G* (encoding epithelial sodium channel γ subunit), were reported to be associated with hypertension [19]. These results suggested that these genes might regulate arrhythmia in KD.

Keshan disease is clinically manifested as systolic and diastolic dysfunction, mainly driven by force-generating mechanism of myocardial contraction and Calcium

handling. This seven-myocardial contraction related genes, *VCL*, *DTNA*, *NEXN*, *MYBPC3*, *GSN*, *MYOT*, and *PRKAG2*, were found to form an interactive network through PPI analysis. In particular, cytoskeleton-related genes (*DTNA*, *NEXN*, and *VCL*) and sarcomere-related gene (*MYBPC3*) were previously reported as causative genes in dilated cardiomyopathy. Moreover, the overexpression of Gelsolin (*GSN*), the actin-binding proteins, enhanced cardiomyoblast cell apoptosis [20]. In addition, the mutant Myotilin (*MYOT*), a Z-disc protein, heavily aggregated together with other Z-disc-related proteins [21]. The above evidence indicated that this interactive network might be essential to maintain the function of myocardial contraction in KD patients.

It is thought that immune-inflammatory mediated cardiomyocyte apoptosis, clinically manifested in Keshan disease. Among these nine immunity related genes (*CANX*, *FUT4*, *GGT1*, *HIF1A*, *INPPL1*, *JAK2*, *NOS3*, *PARP1*, and *TFRC*), the two cores *JAK2* and *TFRC* were found to form an interactive network. The activation of *JAK2* induced apoptosis of myocardial cells under oxidative stress [22]. In addition, the calnexin (*CANX*) was essential for autoimmune in mice [23]. The above evidence suggested that these genes might regulate immune process to influence cardiomyocyte apoptosis.

Se deficiency was thought to closely connect with KD, indicating Se-related genes might play a critical role in the process of Keshan disease. Notably, three candidate Se-related genes, Gelsolin (*GSN*), α -adducin (*ADD1*), and nitric oxide synthase 3 (*NOS3*), were determined as most likely pathogenic genes in KD. For example, the overexpression of *GSN* enhanced cell apoptosis and induced cardiomyocyte hypertrophy. KD tends to be accompanied by cardiac hypertrophy and cardiac cell apoptosis, indicating *GSN* might mediate these phenotypes in KD [20]. Moreover, *ADD1*-deficient mice triggered hypertension [24]. In addition, it is identified *NOS3* polymorphisms and an increase in *NOS3* gene expression in DCM, and *NOS3* generates nitric oxide (NO) for vascular smooth muscle relaxation [25]. Thus, although these three genes have not directly related to Keshan disease, the above evidence indicates that these genes may be involved in the occurrence and development of Keshan disease.

The gene *ALAD* encodes δ -aminolevulinic acid dehydratase (ALAD), which is composed of 8 identical subunits and is the key enzyme in the second step of heme synthesis [26]. Hemoglobin is a key protein that carries and transports oxygen in the body with protoporphyrin IX (heme) as a prosthetic group [27]. Its main functions are oxygen transfer, electron transfer, and biosensor. If the activity of ALAD is abnormal, it will hinder the synthesis of hemoglobin and cause a series of diseases [28,29].

It should be pointed out that myoglobin, which is homologous to hemoglobin, only exists in the myocardium and striated muscle, with heme as a prosthetic group, and its biological function is to help myocardial cells transport oxygen to mitochondria [27]. In addition, the hypoxic HIF-1 signaling pathway was extensively enriched, *ALAD* and HIF-1 α constitute a protein-protein interaction network, and the ATP biosynthetic pathway was enriched in this study. Furthermore, the *ALAD* homozygous mutants were lethal before the formation of the atrial septum, indicating that *ALAD* is important in the development of the heart, which suggested it might play an important role in the pathogenesis of KD.

Nevertheless, further functional experiments are required to investigate the molecular mechanisms related to these candidate genes. Our study offers gene-wide mutation data that will aid our understanding of KD pathogenesis and be a useful source of drug targets for KD treatment.

4. Materials and Methods

4.1 Collection of peripheral blood samples

Patients with KD were enrolled in Miren County and Renhe District at Sichuan Province in China in the period from 2016 to 2018. 100 unrelated ethnically matched healthy subjects recruited from the Sichuan Provincial People's Hospital. Any patients diagnosed with KD patients using defined KD criteria in China (WS/T 210–2011). Cardiac functions of all the endemic area subjects were classified referring to the NYHA (New York heart association) classification method. Whole blood samples from 68 KD patients and 100 normal controls were collected in heparinized vacutainer tubes. Enrolled patients need to sign an informed consent form. The research was approved from the ethics committee of the Sichuan Academy of Medical Sciences and the Sichuan Provincial People's Hospital.

4.2 Whole- exome sequencing, variant selection, and annotation

Briefly, we purified DNA from peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). Whole-exome enrichment was performed with SureSelect Human All Exon kit V6 (Agilent Technologies, Santa Clara, CA, USA). Genomic DNA library was carried out to sequence using the Illumina's HiSeq X and NovaSeq system (Illumina, San Diego, CA, USA). The sequenced DNA fragments were aligned with Human Reference Genome (NCBI Build 37) based on the Burrows–Wheeler transform. Removal of duplication, realignment, and recalibration were performed according to Picard tools (<http://picard.sourceforge.net/>), GATK (http://www.broadinstitute.org/gsa/wiki/index.php/Home_Page). The calling of single Nucleotide Polymorphism (SNP) and insertion-deletion polymorphisms (indels) was performed using GATK3.7 software. The high-confidence variants were annotated with snpEff (Version 4.2; <http://snpeff.sourceforge.net/>). In addition, the annotations of all variants were further performed using 1000 Genomes Project data (2014 Oct release, <http://www.1000genomes.org>), the Exome Aggregation Consortium (ExAC; <http://exac.broadinstitute.org>), EVS (<http://evs.gs.washington.edu/EVS>), The ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar>) database, and Online Mendelian Inheritance in Man (OMIM, <http://www.omim.org>).

4.3 Rare variants of DCM-causative genes

In total, 98 DCM-causative genes were chosen to analyze rare variants in Keshan cases and control subjects[12,13]. These genes were considered as reference genes according to at least one of the following criteria: (1) the dysfunction of these genes led to dilated cardiomyopathy, (2) animal experiments verify the phenotype of dilated cardiomyopathy. The selected DCM-causative genes were shown in Supplementary Table S1.

4.4 Gene-based burden analysis and enriched diseases analysis for rare variants

To analyze the aggregate association of rare variants in gene level, we performed gene-based burden analysis to obtain a gene-level mutational profile with unrelated Keshan cases ($n = 68$) and control subjects ($n = 100$). Rare variants were defined as ‘deleterious variants’ with $MAF < 0.01$. The statistical method uses Fisher’s exact test to evaluate gene-based burden analysis. A gene-level mutational profile was calculated according to 1000 Genomes Project data and ExAC with $MAF < 0.001$, $MAF < 0.01$, or $MAF < 0.05$; $p\text{-value} < 0.05$. All the significant genes were inputted to the Comparative Toxicogenomics Database (CTD; <http://ctdbase.org>) to obtain candidate gene lists with cardiovascular enriched diseases. The candidate genes were submitted to Reactome (<http://www.reactome.org>) to calculate the rich factor, and the top 30 enriched pathways were exhibited with the corrected p value. Protein–protein interactions of the candidate genes were further detected by the STRING database (see <http://apps.cytoscape.org/apps/stringapp>), and visualized it with Cytoscape v2.3 software.

4.5 Screening of the Se-related genes in gene-based burden results

Se deficiency was closely linked to the occurrence of Keshan disease; we further input all the genes into CTD database from gene-based burden analysis with $MAF < 0.001$, $MAF < 0.01$, or $MAF < 0.05$; $p\text{-value} < 0.05$. Then, Se- related proteins were screened through CTD database. A Venn analysis was further conducted to obtain

Se-related pathogenic genes through comparing Se-related proteins with candidate pathogenic genes from enriched diseases analysis.

Reference

1. Zhou B, He S, Wang XI, *et al.* Metabolism of arachidonic acid by the cytochrome P450 enzyme in patients with chronic Keshan disease and dilated cardiomyopathy. *Biomed Rep.* 2016, 4: 251.
2. Zhu Y, Lai B, Niu X, *et al.* Long-term prognostic value of major and minor ECG abnormalities in latent Keshan disease with suspect chronic Keshan disease. *J Epidemiol.* 2014, 24: 385–391.
3. Lei C, Niu X, Wei J, *et al.* Interaction of glutathione peroxidase-1 and selenium in endemic dilated cardiomyopathy. *Clin Chim Acta.* 2009, 399: 102-108.
4. Burke MP, Opeskin K. Fulminant heart failure due to selenium deficiency cardiomyopathy (Keshan disease). *Med Sci Law.* 2002, 42:10.
5. Sung SZ. The relationship between seasonal prevalence of Keshan disease and hair selenium level of local inhabitants. *Zhonghua Yu Fang Yi Xue Za Zhi.* 1980, 14:17-9.
6. Ge K, Yang G. The epidemiology of selenium deficiency in the etiological study of endemic diseases in China. *Am J Clin Nutr.* 1993, 57: 259S-263S.
7. Sun Y, Gao C, Wang X, *et al.* Preliminary quantitative proteomics analysis in chronic and latent Keshan disease by iTRAQ labeling approach. *Oncotarget.* 2017, 8:105761-105774.
8. Lei C, Niu X, Ma X, *et al.* Is selenium deficiency really the cause of Keshan disease? *Environ Geochem Health.* 2011, 33: 183-188.
9. Luo R, Zheng C, Yang H, *et al.* Identification of potential candidate genes and pathways in atrioventricular nodal reentry tachycardia by whole-exome sequencing. *Clin Transl Med.* 2020, 10: 238-257.
10. Cirulli ET. The increasing importance of gene-based analyses. *PLoS Genet.* 2016, 12: e1005852.
11. Moutsianas L, Agarwala V, Fuchsberger C, *et al.* The power of gene-based rare variant methods to detect disease-associated variation and test hypotheses about complex disease. *PLoS Genet.* 2015, 11: e1005165.
12. Reichart D, Magnussen C, Zeller T, *et al.* Dilated cardiomyopathy: from epidemiologic to genetic phenotypes. *J Intern Med.* 2019, 286: 362-372.

13. Mazzarotto F, Tayal U, Buchan RJ, *et al.* Reevaluating the genetic contribution of monogenic dilated cardiomyopathy. *Circulation*, 2020, 141: 387-398.
14. Wang S, Yan R, Wang B, *et al.* Prediction of co-expression genes and integrative analysis of gene microarray and proteomics profile of Keshan disease. *Sci Rep*. 2018, 8: 231.
15. Chambers JC, Zhao J, Terracciano CMN, *et al.* Genetic variation in SCN10A influences cardiac conduction. *Nat Genet*. 2010, 42: 149-152.
16. Giuseppe DS, Pietro P, Stefano C, *et al.* Sudden cardiac death in J wave syndrome with short QT associated to a novel mutation in Na v 1.8 coding gene SCN10A: First case report for a possible pharmacogenomic role. *J Electrocardiol*. 2018, 51: 809-813.
17. El-Battrawy I, Jonas Müller, Zhao Z, *et al.* Studying Brugada Syndrome with an SCN1B variants in human-induced pluripotent stem cell-derived cardiomyocytes. *Front Cell Dev Biol*, 2019, 7: 261.
18. Refsgaard L, Olesen M, Mller DV, *et al.* Mutation analysis of the candidate genes SCN1B-4B, FHL1, and LMNA in patients with arrhythmogenic right ventricular cardiomyopathy. *Appl Transl Genom*. 2012, 1: 44-46.
19. Peng F, Xiao-Cheng P, Di Z, *et al.* Pediatric Liddle Syndrome caused by a novel SCNN1G variant in a Chinese family and characterized by early-onset hypertension. *Am J Hypertens*. 2020, 33: 670-675.
20. Yeh YL, Hu WS, Ting WJ, *et al.* Hypoxia augments increased HIF-1 α and reduced survival protein p-Akt in Gelsolin (GSN)-dependent cardiomyoblast cell apoptosis. *Cell Biochem Biophys*. 2016, 74: 221-228.
21. Garvey SM, Miller SE, Claflin DR, *et al.* Transgenic mice expressing the myotilin T57I mutation unite the pathology associated with LGMD1A and MFM. *Hum Mol Genet*. 2006, 15: 2348-2362.
22. Huang G, Huang X, Liu M, *et al.* Secoisolariciresinol diglucoside prevents the oxidative stress-induced apoptosis of myocardial cells through activation of the JAK2/STAT3 signaling pathway. *Int J Mol Med*. 2018, 41: 3570-3576.
23. Paskevicius T, Jung J, Pujol M, *et al.* The Fabp5/calnexin complex is a prerequisite

- for sensitization of mice to experimental autoimmune encephalomyelitis. *FASEB J.* 2020, 34: 16662-16675.
24. Marro ML, Scremin OU, Jordan MC, *et al.* Hypertension in beta-adducin-deficient mice. *Hypertension.* 2000, 36: 449-53.
25. Matsa LS, Rangaraju A, Vengaldas V, *et al.* Haplotypes of NOS3 gene polymorphisms in dilated cardiomyopathy. *PLoS One.* 2013, 8: e70523.
26. Thunshelle C, Yin R, Chen Q, *et al.* Current Advances in 5-Aminolevulinic Acid Mediated Photodynamic Therapy. *Curr Dermatol Rep.* 2016, 5:179-190.
27. andschin C, Lin J, Rhee J, *et al.* Nutritional Regulation of hepatic heme biosynthesis and porphyria through PGC-1 α . *Cell,* 2005, 122: 505-515.
28. Thomasino JA, Zuroweste E, Brooks SM, *et al.* Lead, Zinc, and erythrocyte δ -aminolevulinic acid dehydratase: Relationships in lead toxicity. *Arch Environ Health.* 2013, 32: 244-247.
29. Ge J, Yu Y, Xin F, *et al.* Downregulation of delta-aminolevulinic acid dehydratase is associated with poor prognosis in patients with breast cancer. *Cancer Sci.* 2017, 108: 604-611.